Tasly Pharmaceutical Group's net income has declined by 10%, and the progress of equity transfer may accelerate | Interpretations

① Tasly Pharmaceutical Group achieved a total operating revenue of 8.498 billion yuan in 2024, a decrease of 2.03% year-on-year; Net income attributable to the parent company was 0.956 billion yuan, a decrease of 10.78% year-on-year. ② The current Shareholders are actively advancing the transfer of shares and have begun to sort out and confirm the actual used Assets and subsidiary Assets of the company.

cls.cnFeb 24 10:10 ET

The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.

① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.

cls.cnJan 6 08:42 ET

Tasly Pharmaceutical Group: Some products are priced down, leading to a decrease in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Straight to the earnings conference

① Due to the overall low prosperity in the pharmaceutical commerce industry, the company's revenue in this sector declined in the third quarter of this year; although revenue in the pharmaceutical industry sector grew year-on-year, the price reduction of some products led to a decrease in gross margin, and the company expects that the gross margin may remain stable in the future. ② Regarding the equity trade matter of the company's major shareholder with china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting the various aspects of this trade.

cls.cnNov 27, 2024 09:29 ET

Clinical results did not meet expectations. Tasly Pharmaceutical Group suspends the eight-year development "marathon" of the new anti-cancer drug | Summary of the announcement.

① Tasly Pharmaceutical Group announced the suspension of the research and development of its anmeimu monoclonal antibody. Since its approval in 2016, the drug has reached the IIb phase of clinical research; ② According to the clinical research results, the efficacy of anmeimu monoclonal antibody did not meet expectations, and other EGFR monoclonal antibody biosimilar drugs face fierce competition; ③ This project also involves Sino Biopharmaceutical's equity participation, with Tasly Pharmaceutical Group and Sino Biopharmaceutical respectively recognizing an impairment loss of 0.162 billion yuan and 14.1448 million yuan in assets.

cls.cnNov 22, 2024 11:06 ET

The net profit of Harbin Pharmaceutical Co., Ltd. has more than tripled in the three quarters: driven by the recovery of health products, sustainability is yet to be tested

Back to normal

wallstreetcnOct 29, 2023 22:18 ET

Tailong Pharmaceutical Co., Ltd. plans to welcome the new owner, Zhengzhou high-tech production investment is planned to become the actual controller.

On September 23rd, Capital State learned that the controlling shareholder of A-share company Tai long Pharmaceutical (600222.SH) signed the "share transfer Framework Agreement". As of the date of this announcement, Zhengzhou Zhongsheng Industrial Group Co., Ltd. (hereinafter referred to as "Zhongsheng Industry"), the company's controlling shareholder, holds 132 million shares of the company, accounting for 23.08% of the company's total share capital, all of which are tradable shares with unlimited sales conditions. Zhongsheng Industries has pledged a total of 50 million shares of the company, accounting for 37.75% of the shares held and 8.71% of the total share capital of the company. The above-mentioned stock pledge is not expected to pose an obstacle to the progress of the transaction.

資本邦Sep 22, 2021 23:54 ET